Cellectis Inc. Announces First Quarter 2024 Financial Results and Investor Conference Call

Are you interested in the latest advancements in biotechnology and gene editing? If so, you’ll want to keep an eye on Cellectis Inc., a clinical-stage biotechnology company that is making waves in the field of cell and gene therapies.

Cellectis recently announced that it will be reporting its financial results for the first quarter of 2024 on May 28, 2024, after the close of the US market. This is an exciting opportunity for investors and those interested in the company’s progress to gain insight into its performance and future prospects.

The company is known for its pioneering gene-editing platform, which is being used to develop life-saving therapies for a variety of diseases. Cellectis is at the forefront of utilizing an allogeneic approach for CAR-T immunotherapies in oncology, as well as developing gene editing in hemopoietic stem cells for other conditions.

With over 24 years of experience in gene editing, Cellectis is a leader in the field and is constantly pushing the boundaries of what is possible in biotechnology. The company’s headquarters are in Paris, France, with additional locations in New York and North Carolina.

If you’re interested in learning more about Cellectis and its groundbreaking work, mark your calendars for the investor conference call and webcast on May 29, 2024. This will be an opportunity to hear about the company’s first quarter results and get an update on its business activities.

For more information on Cellectis, including how to participate in the conference call, visit their website or contact their media or investor relations teams. Stay tuned for more exciting developments from this innovative biotechnology company.